StemCell Therapy

When I first took a glance at businessman Andrew Yang, I immediately dismissed him as a hyper-leftist. He supported Medicare-for-All, the most radical healthcare plan being proposed by some of the Democratic candidates. But like others in the field, Yang has walked back his support for Medicare-for-All. His newly released healthcare plan is by far the most moderate being proposed by anyone polling over nil. Its more moderate than Pete Buttigiegs Medicare For All Who Wants It. Its more moderate than Joe Bidens Obamacare 2.0. In fact, its the only plan that, if proposed by Democrats and Republicans together, would likely pass with massive bipartisan support if one component was stripped from it.

Dont get me wrong. Im not a Yang supporter. I have issues with other policies hes proposing and would actually enjoy a conversation with him over a couple that make very little sense to me. But I can say this about the candidates proposals: Hes the only one in the field who could appeal to right-leaning Independents and moderate Republicans in the general election. Polls say that person is either Biden or Buttigieg, but heres the catch: When people start taking a closer look at the policy proposals theyve backed themselves into in an attempt to appease the far-left in their party, those policies wont hold up to scrutiny. They are to the left of President Obama and candidate Hillary Clinton. Theyre much further to the left than anything this country has ever seen in the White House.

Biden and Buttigieg only seem moderate because the scale has been so skewed by the Democratic Socialist wing that extreme views seem tame compared to the radicals. Yang, on the other hand, has as his branded position the Freedom Dividend, a concept that has been examined by many conservative economists. Milton Friedman proposed a variation of universal basic income in the form of negative tax rates. Others have said it could work if cuts were made to other avenues of spending. A current Republican lawmaker recently told me off the record that if it could be used to reduce the need for welfare, it could actually work well.

What Yang unveiled today as A New Way Forward for healthcare in America is a six-point plan that makes sense. Id strongly recommend Representative Kevin McCarthy and Senator Mitch McConnell give it a serious look.

Here are the bullet points to his six ideas with my commentary below.

The last two ideas are great. Theres a great risk with the others, at least in a vacuum, because healthcare innovation is driven by profits. This is good and bad, but Yangs proposal doesnt address either. Its good thatpharmaceutical research isprofit-driven because it allows for the generation of more funds that private companies can reinvest into more breakthroughs. The bad part is it puts an emphasis on treatments over cures. Treatments are profitable as theyre ongoing. Cures are inherently not profitable.

To truly address the prescription drug issue, incentives need to be established that take advantage of American ingenuity and resources while keeping DCs hands out of it. There have been a handful of proposals Ive read over the years that would drive innovation while also guiding it towards cures and prevention rather than super-profitable ongoing treatments.

These are no-brainers. The only nitpicking I could do would be to take out the broadband access component. It tastes too much like recently proposed Internet for All schemes that suggest spending huge infrastructure dollars to provide digital access to people who simply dont want it. Nobody moves to the boonies in Montana with the expectation of streaming Netflix. They did so for a reason. Those who have intense medical needs wont be hours from the nearest town. Its a pointless addition to the plan. Otherwise, spot-on.

Conservatives may be scared of the idea of federal regulations and licensing. But the plan does not call for the elimination of state medical requirements and licencing. As long as he allows states to regulate their doctors as they see fit but allows for separate telehealth-only licensing and regulations, it passes the federalism smell-test.

Theres a whole lot to unpack here. Capitation and salary plans can work on a small scale but have never been tested on larger scales. There are many risks, especially if it will be the federal government implementing these changes. Were talking about an ideal system in the long-term that could suffer cataclysm on the road to getting there. Its conspicuous that he uses the words work with and explore in the first two bullet points instead of mandate and implement. Such a move could be great if steady hands over a period of time longer than a president can be in the Oval Office were handling it. Thats a lot to ask of DC, but the spirit of the plan is acceptable.

Frivolous malpractice suits yep. No objections to protecting doctors in this regard.

Fix EHR yep. The system is flawed without any good reason other than nobody has addressed it.

There are several slippery slopes in the last three bullet points. Hes describing getting further involved in the way states handle healthcare for their residents. Its a populist concept that would need to be handled carefully. His last two bullet points would shift the job market tremendously. It would raise the costs of hiring specialists because of higher demand and could cause an imbalance of too many primary care physicians.Such programs would have to belimited and adjusted on the fly as needed.

The first bullet point isnt policy, nor should it be. Doctors will do as doctors will do and Ive never met one who didnt tell me to eat better and exercise.

Id want to learn more about the incentives he proposes in the second bullet point. It seems like a nothingburger (or nothingpomegranate, if you prefer) that could eventually lead back to Michelle Obamas school meal decadence plan.

More funding for food banks is good. Better management of charities to feed the needy would be better.

As for the end-of-life proposals, yes, were at a stage in society when all of these ideas make sense. We are better at keeping people alive than we are at maintaining an acceptable quality-of-life. As long as he doesnt get into assisted suicide, these are all positive changes.

The first seven bullet points on mental health and disabilities are good.

Breaking the TRUVADA patent is dangerous only because it sets a precedent. Yes, its important, but the last thing we need is for pharmaceutical companies to pull back the reins on treatments or prevention options because they believe theyre going to lose profits when the government decrees their patents are void.

Then, theres the abortion component. Remember when I said above that one component would have to be stripped? This is it. Yang needed to include it if he has any chance of winning the nomination, but its a non-starter for millions of Americans, including me.

Covering maternity costs is another populist view that would require a full cost analysis to see if its even possible.

Including vision and dental should not be mandated. Theres already a vibrant and affordable market for coverage. This isnt solving a problem. It just mandates convenience at unnecessary expense. It wont save anyone money and could end up costing more as theprices associated are hidden.

Selling a public option as reducing burden on employers is smart. I dont agree with it as the burden would be transferred to taxpayers, but since Republicans seem to no longer be in the business of repealing Obamacare, this really wouldnt be much of a change from the status quo.

So, the $100 Democracy Dollars incentive is odd, but only because I probably dont understand how it works. Call me obtuse. Everything else in his portion of his plan makes sense and should be extended outside of healthcare.

Lawmakers on both sides of the aisle should take a look at Andrew Yangs plan. Its the only healthcare proposal from a Democrat that isnt ludicrous. Considering what Capitol Hill has done with healthcare (nothing), this is worth a peek.

We are currently forming the American Conservative Movement. If you are interested in learning more, we will be sending out information in a few weeks.

See the article here:
Healthcare2 days ago Andrew Yang's healthcare plan could pass today with bipartisan support - NOQ Report

A new multicentre study will investigate the link between brain inflammation and psychosis, and use artificial intelligence techniques to identify patients that might benefit most from novel treatments.

The study, funded by UKRI Medical Research Council, is led by the Universities of Birmingham and Cambridge. Researchers will examine how and if activated inflammatory cells may act differently in psychosis. For example, how they behave in circulation (blood), or whether they cross into the brain and activate immune defence cells and systems.

It is possible these mechanisms could lead to psychosis, and understanding this link could open up new treatment options that target the bodys immune system.

Existing research has shown that some people with psychosis will also have evidence of an activated inflammatory system before and during the early stages of their condition. There is also evidence that inflammation may be related to mood symptoms such as depression, which are common in psychosis.

Psychosis treatment using anti-inflammatory drugs have led to mixed results, however. This is potentially because they were given to patients with psychosis regardless of whether there was evidence of inflammation.

The PIMS (Psychosis Immune Mechanism Stratified Medicine) study will look more closely at the links between inflammation and psychosis and explore how AI techniques can help identify the patients who would benefit most from anti-inflammatory treatment.

Rachel Upthegrove, Professor of Psychiatry in the University of Birminghams Institute for Mental Health, says: New and more effectively targeted treatments are desperately needed for people with psychosis. Evidence suggests that inflammation may be present before and during the early stages of psychosis in some, but not all young people. Through the PIMS study, we are examining how immune dysfunction could be causally related to some symptoms of psychosis, and use Machine Learning and other AI techniques to identify who might benefit most from novel immune targeted treatments.

Dr Golam Khandakar, in the Behavioural and Clinical Neuroscience Institute at the University of Cambridge, says: Around one third of patients with schizophrenia do not get better with current antipsychotic medications. I am excited about working with colleagues at Birmingham and other universities involved in the PIMS project to try and understand whether in future we could target the immune system as a useful way of treating patients with schizophrenia.

Sathnam Sanghera, The Times journalist and author of The Boy in the Topknot, a family memoir about growing up in Wolverhampton in his Punjabi sikh family and about how he didnt know his father and sister had schizophrenia until he was around 30, commented: People talk quite a lot nowadays about the issue of stigma in relation to mental illness. If someone has psychosis they will have the kind of symptoms youll cross the street to avoid or theyll have the kind of symptoms that will make you scared of someone you love. We need funding for more research and new treatments and thats why this study is so important for people suffering like my father and my sister.

Zaynab Sohawon is a member of the Institute for Mental Healths Youth Advisory Group, a group of young people working with Birmingham researchers to create, shape and challenge research into youth mental health. Shesaid: My story started off with adverse childhood experience which led to my mental health deteriorating. This research will help others like me in achieving early intervention in psychotic illnesses.

See the rest here:
Could AI help develop personalised psychosis therapies? - University of Birmingham

Gene therapy is a way of delivering healthy genes or genetic material to cells in order to treat genetic disorders. The most common way to do this is using adeno-associated viruses (AAVs). The outer part of the virus, called the capsid, is generally retained, but the viral genes are replaced with the therapeutic genes. Attempts have been made to improve the capsid or shell of the virus, but usually fail. George Church and his team at Harvard Medical School with the original researchers at the Karolinska Institute and Lund University in Sweden, have developed a technique to modify the capsid. They have also launched a company, Dyno Therapeutics, to develop the approach.

The groups research, by senior author Tomas Bjrklund, with Lund, was published in PNAS, the Proceedings of the National Academy of Sciences of the United States of America.

The technique allows the researchers to engineer the virus shell to deliver the gene package to the exact cell type in the body they intend to treat. The process leverages computer simulations and modeling with gene and sequencing technology.

Thanks to this technology, we can study millions of new virus variants in cell culture and animal models simultaneously, Bjorklund said. From this, we can subsequently create a computer simulation that constructs the most suitable virus shell for the chosen applicationin this case, the dopamine-producing nerve cells for the treatment of Parkinsons disease.

The technique also dramatically decreases the need for laboratory animals. The millions of variations on the same therapy can be studied in the same individual.

The authors wrote, A challenge with the available synthetic viruses used for the treatment of genetic disorders is that they originate from wild-type viruses. These viruses benefit form infecting as many cells as possible in the body, while therapies should most often target a particular cell type, for example, dopamine neurons in the brain.

Current approaches to finding the most advantageous viruses for gene therapy use random screening, enrichment and, the authors say, serendipity. Their technique is dubbed BRAVE (barcoded rational AAV vector evolution). In BRAVE, each virus displays a peptide derived from a protein. That peptide as a known function on the AAV shell surface and what they call a unique molecular barcode in the packaged genome.

By sequencing the RNA-expressed barcodes, they can map the binding sequences from hundreds of proteins simultaneously. They liken the technique to accelerating evolution from millions of years to just weeks.

Bjorklund said The reason we can do this is that we study each generation of the virus in parallel with all the others in the same nerve cells. Unlike evolution, where only the best suited live on to the next generation, we can also learn what makes the virus work less well through this process. This is crucial when building computer models that interpret all the information.

The study showed the potential for using machine learning for AAV design, although the research fell short of actually designing an improved AAV that could be used in clinical testing. Thats where Dyno Therapeutics comes in, working to improve and develop the technique.

Luk Vandenberghe, director of the Grousbeck Gene Therapy Center at Massachusetts Eye and Ear, told C&EN, Chemical & Engineering News, What theyve done here is truly a remarkable tour de force.

Go here to see the original:
Dyno Therapeutics Launches to Improve Viral Vectors for Gene Therapy - BioSpace

Harvard biologist George Church already needed to apologize for a palling around with Jeffrey Epstein even after the financier pleaded to responsible for preying on minors a decade in the past. Now hes elevating eyebrows once morewith plans for a genetics-based courting app.

In an interview with 60 Minutes, Church stated his expertise would pair people based on the propensity of their genes, when mixed in kids, to remove hereditary ailments. Yuko, in contrast, the app, as described, to the Nazi purpose of cultivating a grasp race: I believed we realized after World War II that we werent going to be doing that, she stated.

The church was a part of the coterie of scientists with whom Epstein ingratiated himself via large donations, and Epstein helped bankroll his lab from 2005 to 2007. Church has admitted he repeatedly met and spoke with Epstein for years after the 2008 plea deal that landed him on the intercourse-offender registry.

Epstein had a twisted take on genetics, internet hosting scientific conferences at which he expressed his want to propagate his personal genome by impregnating as much as 20 girls at a time at his New Mexico ranch, like cattle inventory.

Within the 60 Minutes interview, Church referred to as his ties to Epstein unlucky and added: You do not all the time know your donors in addition to you want to.

However, a lot of the phase was dedicated to Churchs genetic-engineering work at Harvard Medical School, together with the app that might theoretically display out potential mates with the improper DNA.

The geneticist didnt drop the apps to identify, or how far alongside its in improvement. He additionally didnt reply to a request for a remark.

Within the interview, the Church acknowledged the drawbacks of genetic sorting. He suffers from dyslexia, consideration deficit dysfunction, and narcolepsyissues that may render him an incompatible match to many. Yuko stated the choice standards could be a sticking level for Churchs app thought.

See the original post:
A New Genetic Based Dating App Will Soon Arrive in The Market - Science Market News

Surge Cities, our second annual ranking of choice metro statistical areas for planting and growing companies, is ostensibly about places. But it's really about people.

For entrepreneurs, what matters is whom you know--also how many you know, how well you know them, how willing they are to help you, and how far you have to go to meet for coffee.

Startup founders with high local connectedness--defined as quality relationships with about 25 other founders, eight investors, and 10 experts--double the revenue growth of those with low connectedness, says Startup Genome, the research and policy organization that is Inc.'s Surge Cities partner. The best way to develop those relationships is through "centers of gravity--places people can meet and build meaningful connections and continue to create value from them," says Arnobio Morelix, Startup Genome's chief innovation officer.

Now, cities vying for entrepreneurial parity with San Francisco, New York, and Boston are engineering their own centers of gravity. Commonly labeled innovation districts, these urban campuses pack in startups and mature companies alongside accelerators and co-working facilities; universities and medical centers; coffee shops, food trucks, outdoor spaces--you get the picture. The operating principle is density. Ideally, smart, creative people bounce off one another in serendipitous "creative collisions" that produce new ideas, relationships, and ventures.

There are roughly 20 substantive innovation districts in the U.S. and more than 100 on the rise worldwide, according to the Brookings Institution. To get an idea how they're serving entrepreneurs, Inc. interviewed three dozen founders in 10 districts around the country. Although a few cited tax credits as the chief advantage (many innovation districts are in opportunity zones), the vast majority said their locations have helped them attract talent, forge partnerships, find early customers, and learn from peers. More developed districts like the St. Louis Cortex Innovation Community, the Chattanooga Innovation District in Tennessee, and Wake Forest's Innovation Quarter in Winston-Salem, North Carolina, earned more love than smaller districts, but no founders regretted their locations.

"The momentum and collaboration over the past 10 years have been amazing to see," says Heidi Jannenga, co-founder and chief clinical officer of WebPT, which develops office-management software for rehab therapists. WebPT was among the first startups in the PHX Core in Phoenix, which today is home to more than 130 companies and six million square feet of research and academic facilities. Like any relatively new district, PHX Core needs to get denser, says Jannenga, and a few more restaurants and other amenities wouldn't hurt. "But what sets us apart" from places like Silicon Valley, she says, "is the generosity. Everyone here is pulling for one another."

The denser the district, the more likely that even the most prosaic activities--attending a networking event, or just crossing the street to get to one--will yield a new customer or business partner. "In this building, there are drug-discovery startups, a company looking at genetic engineering in agriculture, and another looking at drug-delivery systems," says Edward Weinstein, co-founder and CEO of Canopy Biosciences, located in the St. Louis Cortex. Canopy now sells its research tools to a number of district startups "because we talk to them every day," he says. "My last company was 10 miles away, and for eight years, we never met folks in the startup scene."

Stephen Culp is the co-founder of four businesses and a nonprofit in an art deco building in Chattanooga's Innovation District. One day, he was refueling at nearby coffee roaster Mad Priest when he accidentally smacked into Drew Belz, founder and CEO of Fancy Rhino, a nearby branding and video-editing business. Over Belz's broken mug, conversation ensued. Now Fancy Rhino is working with Delegator, Culp's digital ad agency, on a proposal for a D.C.-based think tank. "The more people run into each other, the more they realize what they have in common," Culp says. "The same is true for companies."

Virtually all entrepreneurs said they'd experienced the kind of informal, peer-to-peer exchanges that provide founders advice and emotional sustenance. That's the collegiality Gabe Cooper missed while launching his first software company in a Phoenix suburb. "We weren't near anyone else doing tech," he says. "So we spent a lot of time flying to Silicon Valley to see other tech entrepreneurs."

Cooper moved to the area that would become the PHX Core in 2012, and two years later launched a second company: donor-management system Virtuous CRM. "Here you can be part of all these conversations--people in the coffee shop are talking about customer acquisition," says Cooper. "One of HubSpot's first employees hangs around here. I can just grab him and say, 'Hey, Dan, how should we comp our sales development reps?' " (That Dan would be HubSpot sales director Dan Tyre.)

This ethos of mutual support is embodied by Venture Caf, a nonprofit that hosts five-hour events every Thursday evening in 10 innovation districts around the world, with more on the way. The events, which attract up to 500 people, are designed to tempt founders from their caves with eclectic programming, product demos, and, most important, conversation with people who may change the course of their companies.

Beyond serendipitous interactions, the other universally cited benefit of innovation districts is access to talent. Every firm we interviewed said the amenities and ambiance in these collaborative cores can make recruiting a breeze.

"There are new buildings. A beautiful park. Food trucks. People riding by on bikes and electric scooters," says Brian Platz, co-founder of Fluree, which makes a blockchain-based data-management platform. The startup, Platz's seventh, is based in the Wake Forest Innovation Quarter, a district of more than 170 companies, built around the old R.J. Reynolds Tobacco manufacturing site. "There is so much more creative energy here," he says. "It allows people to imagine themselves hanging out and living here."

As co-founder of a St. Louis design and management consultancy in 2013, Sean Walsh learned that large companies like Monsanto needed outsourced teams of creative, energetic people for software and A.I. projects. Trouble was, he was located in a nondescript, suburban office park, where creative, energetic people didn't want to be caught dead. "I said to my co-founders, 'We're going to start a new company from scratch in the Cortex, because that's where innovative people want to be,' " Walsh says. In 2016, he launched this new company, 1904Labs, in the innovation district, and now it has 85 employees.

Many innovation districts are developed in conjunction with universities or academic medical centers, which act like a virtuous ozone layer, trapping talent and intellectual property so they can't escape the neighborhood. That means abundant interns, but also chances to expand the workforce through collaboration and recruitment. In the Wake Forest district, Jennifer Byrne helped develop a master's program in clinical research at Wake Forest University that she expects to someday supply employees for Javara Research, her platform for improving patient enrollment in clinical trials.

The new Providence Innovation & Design District, in Rhode Island, boasts an unusual variety of academic institutions, including Brown, Johnson & Wales, and the Rhode Island School of Design. "I can hit all of them from here with a baseball," says Adam Alpert, co-founder and CEO of Pangea.app, a platform for matching companies with college students. "I have a little foldable table, and if I have two hours free, I will walk over there and talk with students and hand out stickers." Alpert recently landed a new head of design this way.

One premise of innovation districts is that startup clusters--particularly specialized ones, like autonomous vehicles in Pittsburgh and agtech in St. Louis--may lure investors to open offices there, or at least to visit. The University City Science Center, a 55-year-old urban research park at the heart of what is now uCity Square in Philadelphia, nurtures many of the district's most promising life-science and technology companies. That includes hosting office hours for regional investors to meet with startups. Nyron Burke, founder and CEO of Lithero, which uses A.I. to ensure the legal compliance of life-science-product marketing, raised $100,000 just by walking into a session with Philadelphia-based investor Ben Franklin Technology Partners. "The Science Center is doing the Lord's work," says Burke. But it's not enough, he adds. "Entrepreneurs leave Philadelphia, because it is hard to raise money here."

The money may come to more innovation districts if they produce large exits.In uCity Square, the big dog leading the pack is Spark Therapeutics, a gene-therapy company that Philly native Jeffrey Marrazzo co-founded in 2013 with support from the Children's Hospital of Philadelphia. Today, Spark employs more than 440 people and occupies 200,000 square feet across five buildings in the district. Currently, Marrazzo is awaiting government approval of a $4.8 billion acquisition by Swiss pharmaceuticals giant Roche. It would be the city's biggest-ever VC-backed exit.

Such exits are "hugely important" for entrepreneurial ecosystems like innovation districts, says Startup Genome's Morelix. He calls them "triggers," because they attract resources and also deepen the pockets of early hires, who often go on to invest locally.

In the past, Marrazzo says, startups based on intellectual property from Philadelphia's academic institutions "inevitably moved outside to the suburbs or, more often, licensed out their IP and re-formed in another city, like Boston or San Francisco." Marrazzo kept Spark in the innovation district to buck that trend. Lately, he says, more VCs have reached out to him about the area.

"San Francisco funds and Boston funds are coming here on a regular, scheduled basis," Marrazzo says. "With further success, maybe they'll want to open offices here, too."

From the Winter 2019/2020 issue of Inc. Magazine

See more here:
Want to Make Your City a Startup Hub? You'll Need to Befriend 25 Founders, 8 Investors, and 10 Experts First - Inc.

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, is hosting an R&D Day today beginning at 8am Eastern Time. During the event, Sangamo executives and scientists plan to provide updates across the Companys clinical and preclinical pipeline, as well as an overview of manufacturing capabilities to support clinical and commercial supply. A live webcast link will be available on the Events and Presentations page of the Sangamo website

The talent, R&D capabilities, manufacturing expertise, and operations infrastructure we have brought to Sangamo have enabled us to advance a genomic medicine pipeline that spans multiple therapeutic areas and now also extends into late-stage development, said Sandy Macrae, CEO of Sangamo. As we make progress in clinical development, we gain insights into the use of our technology and are applying those insights as we advance new programs, such as the gene therapy for PKU and the genome regulation candidates for CNS diseases we are announcing today.

Macrae continued: We will continue to pursue a dual approach of retaining certain programs for our proprietary pipeline while also establishing pharmaceutical partnerships to gain access to therapeutic area expertise and financial, operational, and commercial resources. Strategic collaborations will be a particularly important consideration as we advance programs for diseases affecting large patient populations.

R&D Day updates on clinical and preclinical pipeline programs:

Gene therapy product candidates for hemophilia A, Fabry disease, and PKU

SB-525 is a gene therapy product candidate for hemophilia A being developed by Sangamo and Pfizer under a global development and commercialization collaboration agreement. The transfer of the SB-525 IND to Pfizer is substantially completed. Pfizer is advancing SB-525 into a Phase 3 registrational study in 2020 and has recently begun enrolling patients into a Phase 3 lead-in study.

At R&D Day, Sangamo executives are presenting data from the SB-525 program which were recently announced at the American Society of Hematology (ASH) annual meeting.

The cassette engineering, AAV engineering and manufacturing expertise which Sangamo used in the development of SB-525 are also being applied to the ST-920 Fabry disease program, which is being evaluated in a Phase 1/2 clinical trial, as well as to the newly announced ST-101 gene therapy program for PKU, which is being evaluated in preclinical studies with a planned IND submission in 2021.

Engineered ex vivo cell therapy candidates for beta thalassemia, kidney transplantation, and preclinical research in multiple sclerosis (MS)

Sangamo is providing an overview of the Companys diversified cell therapy pipeline this morning. Cell therapy incorporates Sangamos experience and core strengths, including cell culture and engineering, gene editing, and AAV manufacturing. At R&D Day, Sangamo scientists today are reviewing the early data presented this month at ASH from the ST-400 beta thalassemia ex vivo gene-edited cell therapy program, which is being developed in partnership with Sanofi.

Sangamo is also providing updates on the companys CAR-TREG clinical and preclinical programs. CAR-TREGS are regulatory T cells equipped with a chimeric antigen receptor. Sangamo is the pioneer in CAR-TREGS, which may have the potential to treat inflammatory and autoimmune diseases. TX200 is being evaluated in the STEADFAST study, the first ever clinical trial evaluating a CAR-TREG cell therapy. Tx200 is being developed for the prevention of immune-mediated organ rejection in patients who have received a kidney transplant, a significant unmet medical need. Results from this trial will provide data on safety and proof of mechanism, building a critical understanding of CAR-TREGS in patients, and may provide a gateway to autoimmune indications such as Crohns disease and multiple sclerosis (MS). Sangamo is also presenting preclinical murine data demonstrating that CAR-TREGS accumulate and proliferate in the CNS and reduce a marker of MS.

In vivo genome editing optimization

Clinical data presented earlier this year provided evidence that Sangamo had successfully edited the genome of patients with mucopolysaccharidosis type II (MPS II) but also suggested that the zinc finger nuclease in vivo gene editing reagents were under-dosed using first-generation technology. Sangamo has identified potential improvements that may enhance the potency of in vivo genome editing, including increasing total AAV vector dose, co-packaging both ZFNs in one AAV vector, and engineering second-generation AAVs, ZFNs, and donor transgenes.

Genome regulation pipeline candidates targeting neurodegenerative diseases including Alzheimers and Parkinsons

Sangamo scientists today are presenting data demonstrating that the companys engineered zinc finger protein transcription factors (ZFP-TFs) specifically and powerfully repress key genes involved in brain diseases including Alzheimers, Parkinsons, Huntingtons, ALS, and Prion diseases. Sangamo is advancing its first two genome regulation programs toward clinical development:

Sangamo scientists are also presenting data demonstrating progress in the development of new AAV serotypes for use in CNS diseases.

Manufacturing capabilities and strategy

Sangamo is nearing completion of its buildout of a GMP manufacturing facility at the new Company headquarters in Brisbane, CA. This facility is expected to become operational in 2020 and to provide clinical and commercial scale manufacturing capacity for cell and gene therapy programs. The Company has also initiated the buildout of a cell therapy manufacturing facility in Valbonne, France. Sangamos manufacturing strategy includes in-house capabilities as well as the use of contract manufacturing organizations, including a long-established relationship with Thermo Fisher Scientific for clinical and large-scale commercial AAV manufacturing capacity.

R&D Day webcast

A live webcast of the R&D Day, including audio and slides, will be available on the Events and Presentations page of the Sangamo website today at 8am Eastern Time. A replay of the event will be archived on the website.

About Sangamo Therapeutics

Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients lives using gene therapy, ex vivo gene-edited cell therapy, and in vivo genome editing and gene regulation. For more information about Sangamo, visit http://www.sangamo.com.

Sangamo Forward Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of United States securities law. These forward-looking statements include, but are not limited to, the therapeutic potential of Sangamos product candidates; the design of clinical trials and expected timing for milestones, such as enrollment and presentation of data, the expected timing of release of additional data, plans to initiate additional studies for product candidates and timing and design of these studies; the expected benefits of Sangamos collaborations; the anticipated capabilities of Sangamos technologies; the research and development of novel gene-based therapies and the application of Sangamos ZFP technology platform to specific human diseases; successful manufacturing of Sangamos product candidates; the potential of Sangamos genome editing technology to safely treat genetic diseases; the potential for ZFNs to be effectively designed to treat diseases through genome editing; the potential for cell therapies to effectively treat diseases; and other statements that are not historical fact. These statements are based upon Sangamos current expectations and speak only as of the date hereof. Sangamos actual results may differ materially and adversely from those expressed in any forward-looking statements. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to dependence on the success of clinical trials; the uncertain regulatory approval process; the costly research and development process, including the uncertain timing of clinical trials; whether interim, preliminary or initial data from ongoing clinical trials will be representative of the final results from such clinical trials; whether the final results from ongoing clinical trials will validate and support the safety and efficacy of product candidates; the risk that clinical trial data are subject to differing interpretations by regulatory authorities; Sangamos limited experience in conducting later stage clinical trials and the potential inability of Sangamo and its partners to advance product candidates into registrational studies; Sangamos reliance on itself, partners and other third-parties to meet clinical and manufacturing obligations; Sangamos ability to maintain strategic partnerships; competing drugs and product candidates that may be superior to Sangamos product candidates; and the potential for technological developments by Sangamo's competitors that will obviate Sangamo's gene therapy technology. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in Sangamos operations. This presentation concerns investigational drugs that are under preclinical and/or clinical investigation and which have not yet been approved for marketing by any regulatory agency. They are currently limited to investigational use, and no representations are made as to their safety or effectiveness for the purposes for which they are being investigated. Any discussions of safety or efficacy are only in reference to the specific results presented here and may not be indicative of an ultimate finding of safety or efficacy by regulatory agencies. These risks and uncertainties are described more fully in Sangamo's Annual Report on Form 10-K for the year ended December 31, 2018 as filed with the Securities and Exchange Commission on March 1, 2019 and Sangamo's Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 that it filed on or about November 6, 2019. Except as required by law, we assume no obligation, and we disclaim any intent, to update these statements to reflect actual results.

Read more:
Sangamo Highlights Advancements in Genomic Medicine Pipeline and Expanded R&D and Manufacturing Capabilities at R&D Day - Business Wire

XconomySan Diego

Nearly nine years ago Jeanne Loring and her colleagues at Scripps Research debuted a test that leveraged advances in genomics and data science to determine, without testing in animals, whether human stem cells were pluripotent, or able to become any type of cell in the body.

Being able to prove that has become increasingly important as scientists look to induced pluripotent stem cells (iPSCs)mature, specialized cells that have been reprogrammed as immature cells, regaining the capability of becoming any type of cellas material for new regenerative medicines.

Now Loring and Andres Bratt-Leal, who joined her lab in 2012 as a post-doctoral researcher, have founded a biotech that combines stem cell biology and genomics know-how to advance a potential cell therapy for Parkinsons disease.

The startup announced Thursday it raised a seed round of $6.5 million to support its work. Aspens lead drug candidate, which is in preclinical testing, is intended to replace neurons in the brains of people with the disease, which causes those cells to become damaged or die.

When people with Parkinsons disease lose neurons, they also lose a chemical messenger the cells produce, called dopamine. Without dopamine, communication between nerve cells falters, which leads to the debilitating motor problems that characterize the disease. Existing Parkinsons drugs aim to alter dopamine levels. Aspen, however, wants to fix the upstream problem that leads to those lowered levels by reconstructing patients damaged neural networks.

The cell therapy would involve harvesting patients own living cells through a skin biopsy, reprogramming them to immature cells, or iPSCs, then further engineering them to become predisposed to mature into neurons. Once enough of those cells have been grown in the lab, those neuron precursor cells would be delivered directly to the brain.

Using a patients own cells avoids the dangerous immune system reactions that can occur when donor cells are used in such therapies, and obviates the need for immunosuppression drugs. Two cell therapies that use genetic engineering have been approved by the FDA, both of which take and tweak patients T cells into treatments for cancer. Stem cell transplants have been used to treat some cancers.

Aspen worked to ensure the company could ably manufacture a so-called autologous replacement cell therapy, or one from a patients one cells, by improving the process of differentiating iPSCs into dopamine neurons, Loring says. And the group developed another predictive genomic-based test, similar to the effort Loring spearheaded nearly a decade ago to determine whether cells were pluripotent, that can detect which iPSCs are destined to become neurons.

(Bratt-Leal) put his biological engineering expertise into coming up with a way that was reproducible, that we would get the same cells no matter who we got the original cells from, she says.

The company plans to test the therapy in patients that they determine, through genomic testing, have the most common form of Parkinsons, which is referred to as sporadic and arises without a clear genetic predisposition. It also has a second treatment in the works that it intends to develop for patients with familial forms of the disease, and uses a gene editing toolyet to be selectedto alter their stem cells during the reprogramming process.

Howard Federoff, who was most recently vice chancellor for health affairs and CEO of the UC Irvine Health system, is Aspens CEO. Federoff says he has come to believe that Parkinsons patients need more than just to stabilize their disease They need to turn the clock back.

Many companies are working on drugs to treat Parkinsons, but most are meant to manage symptoms rather than reverse the disease. Levodopa, which supplants missing dopamine, is used widely, but it can cause side effects, including involuntary movement called dyskinesia; and, as the disease progresses, the drug eventually stops working between doses.

Aspen claims it is the only company working toward an autologous neuron replacement. The company, however, will need to raise a Series A round to move its drug candidates through Phase 2 proof-of-concept trials, Loring says.

The company raised its seed round from a group of investors including Domain Associates, Alexandria Venture Investments, Arch Venture Partners, Axon Ventures, OrbiMed, and Section 32. Initially, it was financed through grants from Summit for Stem Cell, a San Diego-based nonprofit.

Sarah de Crescenzo is an Xconomy editor based in San Diego. You can reach her at sdecrescenzo@xconomy.com.

Continued here:
Aspen Neuro Bags $6.5M to Test Parkinson's Disease Stem Cell Therapy - Xconomy

And speaking of both Disney+ and Star Wars, that combination resulted in the most-watched show of any of the streaming services, The Mandalorian. Oh, and then there's Baby Yoda. Which brings us to the most recent reason Iger is having a good year: he was just named Time's Businessperson of the Year. Make no mistake, Baby Yoda is a perfect example of why that honorwas well-earned.

The Time article tells a brief story of how Iger knew immediately Baby Yoda would be an enormous hit with fans. For Disney, by the way, enormous hits are the standard operating procedure. In fact, the entire strategy looks something like this:

Create a story with adorable characters. Mass market both the story and the characters. Manufacture merchandise featuring adorable characters. Stuff more cash than you can imagine into the bank account.

In the case of Baby Yoda, Iger not only knew that the character would lead to huge sales, but also that the best play was radio silence until after the first episode of The Mandalorian streamed, so as not to spoil the reveal.

He wasright, of course.

Look, regardless of what you think of the mysterious green alien that has become the star of the Disney+ service and the mascot of the internet, there's really no arguing that from a business standpoint, Baby Yoda is brilliant. And it's a great lesson for entrepreneurs.

Here's why: Bob Iger isn't a storyteller--at least not in the classic sense of someonewho writesa scriptor directs a film. That isn't his role.But he has one thing that might be even more important--a sense of how stories connect with audiences. I'm not sure anyone would disagree that Iger knows his audience, and knows how to steward both the Disney brand as a whole, as well as the individual stories within it (Star Wars, Marvel, etc.)to make sure they resonate with that audience.

But Iger didn't create The Mandalorian or its most famous character. He didn't invent streaming video. He didn't dream upthe Star Wars universe. He isn't a comic book illustrator.

The puzzle that makes up Disney has an extraordinary number of pieces, none of which originated with its CEO. Instead, Iger's job is to see how all of those pieces fit together, and sell the resulting picture tothe rest of us.

And, just because you aren't running the world's largest media and entertainment company, doesn't mean that you don't have a story to tell.And, it doesn't mean you can't learn from what made Bob Iger so successful this year.

In most of the areas Disney competes, it is the apex predator. It's the biggest player in theme parks. It's the biggest licensor of toy characters. It's the biggest sports broadcaster. It's the biggest animation studio. It's the biggest family-friendlymovie producer.

It is not the biggeststreaming video service. It isn't the biggest player--Netflix has over 150 million subscribers--a number that dwarfs Disney+. But it made a huge bet that owning its own platform to stream its own library of content would pay off in a big way.

So far it has. And the lesson here is that when you align your story with your audience, you will win.

That's one of the most important qualities in any marketer, but also in every entrepreneur. Your primary job, at least at first,is to figure out how to tell the story of your brand, and then tell it to the right audience.

And you don't even need Baby Yoda for that--but it can'thurt.

The opinions expressed here by Inc.com columnists are their own, not those of Inc.com.

Visit link:
Disney's Bob Iger Was Just Named Time's Businessperson of the Year and Baby Yoda Is Exactly the Reason Why - Inc.

Christmas Is A Season Not Only Of Rejoicing But Of Reflection. Avail Up To 40% Off On All Our Qualitative Research Reports. Be the Santa of Your Happy Business!

Worldwide Genetic Engineering Drug Market is a report created by Global Marketers.Biz. The Genetic Engineering Drug market research report is segmented on the basis of device, technology, application, and region. Primary and secondary research efforts were invested to arrive at intelligent conclusions presented in the report on the global target market. Findings and conclusions of the research were verified by experts from the industry before including it in the report.

It is a compilation of analytical study based on historical records, current, and upcoming statistics and future developments of the Genetic Engineering Drug Industry. Based on the study, Global Marketers.Biz predicts that the market will see a comparable and steady CAGR growth.

Genetic Engineering Drug Market Segmentation By Type, Applications & Regions

Fill Out Details To Receive FREE Sample Report Copy Here: https://www.globalmarketers.biz/report/life-sciences/global-genetic-engineering-drug-industry-market-research-report/4570 #request_sample

The report covers a forecast and an analysis of the Genetic Engineering Drug Market on a global and regional level. The ancient data is given from 2013-2018 and the estimate period is from 2019-2023 based on revenue (USD Billion). The Genetic Engineering Drug market was estimated at XX Million US$ in 2019 and is probable to grasp XX Million US$ by 2023, at a CAGR of XX% throughout 2019-2023.

The study is also compiled on the basis of the latest and upcoming innovations, opportunities and trends. In addition to SWOT analysis, the report also contains a detailed market analysis outlining every major player in the process.

Avail Up To 40% Off On All Our Qualitative Research Reports.

Inquire Before Buying Or Ask For More Details: https://www.globalmarketers.biz/report/life-sciences/global-genetic-engineering-drug-industry-market-research-report/4570 #inquiry_before_buying

The Report Answers the key Questions related to the Genetic Engineering Drug Market:

What are the important trends and dynamics?

Where will most development take place in the long term?

What does the competitive landscape look like?

What the openings are yet to come?

TOC of Genetic Engineering Drug Market Report Includes:

1. Industry Overview of Genetic Engineering Drug

2. Industry Chain Analysis of Genetic Engineering Drug

3. Manufacturing Technology of Genetic Engineering Drug

4.Major Manufacturers Analysis of Genetic Engineering Drug

5. Global Productions, Revenue and Price Analysis of Genetic Engineering Drug by Regions, Creators, Types and Applications

6. Global and Foremost Regions Capacity, Production, Revenue and Growth Rate of Genetic Engineering Drug 2013-2019.

7. Consumption Volumes, Consumption Value, Import, Export and Trade Price Study of Genetic Engineering Drug by Regions

8. Gross and Gross Margin Examination of Genetic Engineering Drug

9. Marketing Traders or Distributor Examination of Genetic Engineering Drug

10. Worldwide Impacts on Genetic Engineering Drug Industry,

11. Development Trend Analysis of Genetic Engineering Drug

12. Contact information of Genetic Engineering Drug

13. New Project Investment Feasibility Analysis of Genetic Engineering Drug

14. Conclusion of the Global Genetic Engineering Drug Industry 2019 Market Research Report

Continued

Finally, the feasibility of new investment projects is assessed, and overall research conclusions are offered.

Customization Service of the Report:

Global Marketers.biz provides customization of reports as per your need. The report can be altered to meet your requirements. Contact our sales team, who will guarantee you to get a report that suits your needs.

Please get in touch with our sales squad (Alex@globalmarketers.biz).

For more relevant information visit https://www.globalmarketers.biz/

Avail Up To 40% Off On All Our Qualitative Research Reports.

Request for more detailed information (TOC and Sample): https://www.globalmarketers.biz/report/life-sciences/global-genetic-engineering-drug-industry-market-research-report/4570 #table_of_contents

Read the rest here:
Global Genetic Engineering Drug Market | 2018-2023 Growth Analysis, Business Opportunities, Sales, Revenue, Gross Margin, Advance Technology and...

Inspiring coaches go for quantity, not quality, of ideas to build a culture of innovation and ownership. They make ideas-;lots of them-;part of everyones job. They use clarifying questions to determine if and how to best implement the ideas.

Ask your team for the kinds of ideas you need. You may have a focus area for that week, month, or quarter. A good place to start is with the eight areas of waste.

Transport-;Moving people, products, and information

Inventory-;Storing parts, pieces, and documentation ahead of requirements

Motion-;Bending, turning, reaching, lifting

Waiting-;For parts, information, instructions, equipment

Overproduction-;Making more than is immediately required

Over-processing-;Tighter tolerances or higher- grade materials than are needed

Defects-;Rework, scrap, incorrect/incomplete information

Skills-;Underutilizing capabilities, delegating tasks with inadequate training

Involve your team in addressing these areas of waste and other opportunities for improvement to enlist their ownership in the solution.

One of mylong-standing clients, Jeff Jensen, manages a portfolio of successful companies. Jeff has shared a favorite quote from his late father, Ron Jensen, who was an innovative and inspiring leader. He liked to say, The biggest room in the world is the room for improvement.

This metaphorical room for improvement can be your business, your teams processes, your teams skills, and most importantly, your own leadership.

The opinions expressed here by Inc.com columnists are their own, not those of Inc.com.

View post:
8 Ways to Reduce Waste - Inc.

The Report Stem Cell and Platelet Rich Plasma (PRP) Alopecia TherapiesMarket provides Key Benefits, Key Market Segments, Secondary and Primary Research, Analyst Tools and Models to 2024. The report will assist reader with better understanding and decision making.

GlobalStem Cell and Platelet Rich Plasma (PRP) Alopecia TherapiesMarketpresented byMRInsights.bizexamines market ecosystem, adoption trends, key drivers, competitive outlook, key challenges, restraints, market share, revenue, opportunities, future growth potentials, and revenue chain analysis. The report delivers data on manufacturers, geographical regions, types, applications. Key players are evaluated considering various parameters like product portfolio, product scope, revenue, share, company overview, sales, contact information, market share from 2013 to2024. Its a must-read for entrepreneurs, investors, consultants, researchers and those who are planning to boost their business in theStem Cell and Platelet Rich Plasma (PRP) Alopecia Therapiesmarket.

DOWNLOAD FREE SAMPLE REPORT:https://www.mrinsights.biz/report-detail/213867/request-sample

The worldwide market is an enlarging field for top market players :Orange County Hair Restoration Center, Hair Sciences Center of Colorado, Evolution Hair Loss Institute, Savola Aesthetic Dermatology Center, Anderson Center for Hair, Colorado Surgical Center & Hair Institute, Virginia Surgical Center, Hair Transplant Institute of Miami

Regional section of this report covers the investigation of various parameters such as production volume, revenue, profit margin, export-import figures, and local consumption in different regional markets. Regions that have been covered for this market:Americas (United States, Canada, Mexico, Brazil), APAC (China, Japan, Korea, Southeast Asia, India, Australia), Europe (Germany, France, UK, Italy, Russia, Spain), Middle East & Africa (Egypt, South Africa, Israel, Turkey, GCC Countries)

Each segment is comprehensively studied in the report concerning market acceptance, market trends, consumption tendencies, profitability, attractiveness, and revenue generation.Drivers and restraints look at the external factors assisting and controlling the growth of the market.Other major covered in this report includes market status (2013-2019), advantages and disadvantages of enterprise products, competition pattern, regional characteristics, industry development trends, industrial policy, and macroeconomic policies. The report mainly focuses on delivering competitive advantages to market players which will help them compete vigorously in the ever-changing business environment.

How This Report Will Help You?

READ FULL REPORT:https://www.mrinsights.biz/report/global-stem-cell-and-platelet-rich-plasma-prp-213867.html

Research objectives

There are 13 Chapters to deeply display the globalStem Cell and Platelet Rich Plasma (PRP) Alopecia Therapiesmarket.

Chapter 1:Scope of the Report

Chapter 2:Executive Summary

Chapter 3:GlobalStem Cell and Platelet Rich Plasma (PRP) Alopecia Therapiesby Manufacturers

Chapter 4:Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapiesby Regions

Chapter 5, 6, 7, 8 and 9:Americas,APAC,Europe,Middle East & Africa,Market Drivers, Challenges and Trends

Chapter 10 and 11:Marketing, Distributors and CustomerAndGlobalStem Cell and Platelet Rich Plasma (PRP) Alopecia TherapiesMarket Forecast.

Chapter 12 And 13 :Key Players Analysis,Research Findings and Conclusion.

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@mrinsights.biz), who will ensure that you get a report that suits your needs.

Read more here:
Global Stem Cell and Platelet Rich Plasma Alopecia Therapies Market 2019 Analysis forecast to 2024 Focusing on Top Key Players Orange County Hair...

Global Synthetic Stem Cells Market Size, Status and Forecast 2019-2025offers a primary overview of the Synthetic Stem Cells industry coveringDefinition, Classification, Industry Value, Price, Cost and Gross Profit, Share via Region, New Challenge Feasibility Evaluation, Analysis and Guidelines on New mission Investment. Synthetic Stem Cells Market report presents in-intensity insight ofCompany Profile, Capacity, Product Specifications, Production Value, Sales, Revenue, Price, Gross Margin, Market Size and Market Sharesfor topmost prime key vendors(North Carolina State University, Zhengzhou University). In the end, there are 4 key segments covered in this Synthetic Stem Cells market report: competitor segment, product type segment, end use/application segment and geography segment.

Target Audience of Synthetic Stem Cells Market:Suppliers, Channel Partners,Production Companies, Market Consultants,Marketing Authorities, Research Institutions, Subject Matter Experts, Financial Institutions, Government Authorities.

To Get the Concise Free Sample PDF of the Synthetic Stem Cells Market Report, Along With the TOC, Statistics, and Tables Please Visit @https://www.researchmoz.us/enquiry.php?type=S&repid=2395700

Synthetic Stem Cells Market Summary:Synthetic stem cells offer therapeutic benefits comparable to those from natural stem cells and could reduce some of the risks associated with stem cell therapies. Additionally, these cells have better preservation stability and the technology is generalizable to other types of stem cells.

Based on Classifications,each type is studied as Sales, Synthetic Stem Cells Market Share (%), Revenue (Million USD), Price, Gross Margin and more similar information.each type, including:

Cardiovascular Diseases Neurological Disorders Other Diseases

Based on the end users/applications,this report focuses on the status and outlook for major applications/end users, sales volume, Synthetic Stem Cells market share and growth rate of Synthetic Stem Cells foreach application, including:

Cancers Wounds and Injuries Musculoskeletal Disorders Blood disorders

Do You Have Any Query Or Specific Requirement? Ask to Our Industry[emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid=2395700

Synthetic Stem Cells Market: Regional Analysis Includes:

Industrial Chain, Sourcing Strategy and Downstream Buyers (2019 2025)

Synthetic Stem Cells Market Capacity, Production, Revenue, Consumption, Export and Import (2019 2025)

Synthetic Stem Cells Market Forecast (2019 2025)

Contact:

ResearchMozMr. Nachiket Ghumare,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email:[emailprotected]

Browse More Reports Visit @https://bit.ly/2Sepby2

This post was originally published on Space Market Research

See the rest here:
Synthetic Stem Cells Market 2019 Global Trend, Segmentation And Opportunities Forecast To 2025 - Space Market Research

The Stem Cell Therapy for Osteoarthritis market report [6 Year Forecast 2019-2025] focuses on Major Leading Industry Players, providing info like Stem Cell Therapy for Osteoarthritis market competitive situation, product scope, market overview, opportunities, driving force and market risks. Profile the top manufacturers of Stem Cell Therapy for Osteoarthritis, with sales, revenue and global market share of Stem Cell Therapy for Osteoarthritis are analyzed emphatically by landscape contrast and speak to info. Upstream raw materials and instrumentation and downstream demand analysis is additionally administrated. The Stem Cell Therapy for Osteoarthritis market business development trends and selling channels square measure analyzed. From a global perspective, It also represents overall industry size by analyzing qualitative insights and historical data.

The study encompasses profiles of major companies operating in the global Stem Cell Therapy for Osteoarthritis market. Key players profiled in the report includes : Mesoblast, Regeneus, U.S. Stem Cell, Anterogen, Asterias Biotherapeutics and so on.

Get Free Sample PDF for more Professional and Technical insights @https://www.researchmoz.us/enquiry.php?type=S&repid2040020

This Stem Cell Therapy for Osteoarthritis market report provides a comprehensive analysis of:Industry overview, manufacturing cost structure analysis, technical data and manufacturing plants analysis, major manufacturers analysis, development trend analysis, overall market overview, regional market analysis, consumers analysis and marketing type analysis.

Scope of Stem Cell Therapy for Osteoarthritis Market:

The global Stem Cell Therapy for Osteoarthritis market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Stem Cell Therapy for Osteoarthritis market based on company, product type, application and key regions.

This report studies the global market size of Stem Cell Therapy for Osteoarthritis in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Stem Cell Therapy for Osteoarthritis in these regions.

This research report categorizes the global Stem Cell Therapy for Osteoarthritis market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors, customers, research findings & conclusion, appendix & data source and Porters Five Forces Analysis.

The end users/applications and product categories analysis:

On the basis on the end users/applications,this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Stem Cell Therapy for Osteoarthritis foreach application, including-

On the basis of product,this report displays the sales volume, revenue (Million USD), product price, Stem Cell Therapy for Osteoarthritis market share and growth rate ofeach type, primarily split into-

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid2040020

(*Fill the form and our sales representative will get back to you for assistance)

Stem Cell Therapy for Osteoarthritis Market : The Regional analysis covers:

The Crucial Questions Answered by Stem Cell Therapy for Osteoarthritis Market Report:

The report offers exclusive information about the Stem Cell Therapy for Osteoarthritis market, based on thorough research about the macro and microeconomic factors that are instrumental in the development of the market. The information featured in this report can answer salient questions for companies in the Stem Cell Therapy for Osteoarthritis market, in order to make important business-related decisions. Some of these questions include:

And Many More.Contact Us:

ResearchMozMr. Nachiket Ghumare,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email: [emailprotected]Follow us on LinkedIn @ http://bit.ly/2RtaFUo

Follow me on : https://marketnews-24.blogspot.com/

Originally posted here:
Stem Cell Therapy for Osteoarthritis Market 2019 by Research, Statistics, Review and Growth to 2025 - Downey Magazine

The Stem Cell Antibody Market report gives an astonishing source to analyze the Stem Cell Antibody market and other fundamental subtleties identifying with it. The examination uncovers the general evaluation and associated ideas of the Stem Cell Antibody market. The report displays a reasonable scenario of the Stem Cell Antibody market, that links applications, proposals, industry chain structure, and definitions. Likewise, it connects the expansive validity of the Stem Cell Antibody market and configurations to a fundamental precision, experiences, and industry-substantiated estimations of the general Stem Cell Antibody market. Additionally, the examination underlines the huge driving business players (Thermo Fisher Scientific, Inc. (U.S.), Merck Group (Germany), Abcam plc (U.K.), Becton, Dickinson and Company (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Cell Signaling Technology, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (U.S.), GenScript (U.S.), PerkinElmer, Inc. (U.S.), Lonza (Switzerland), and BioLegend, Inc. (U.S.)) across the globe with clear affiliation profiles, data of the wide-ranging business, item type, conditions, and courses of action.

The Stem Cell Antibody market report more focuses on top industry leaders and explores all essentials facets of competitive landscape. It explains potent business strategies and approaches, consumption propensity, regulatory policies, recent moves taken by competitors, as well as potential investment opportunities and market threats also. The report emphasis crucial financial details of major manufacturers including year-wise sale, revenue growth, CAGR, production cost analysis, and value chain structure.

Interesting? Apply for a sample report: http://www.marketsnresearch.com/request-for-sample.html?repid=50557

The manufacturing base, Stem Cell Antibody Industry chain view, raw material cost, labor cost, and downstream buyers analysis is represented. The production and market share by type and application from 2019-2025 are presented in this study. Also, the consumption ratio, gross margin analysis, and import-export statistics are portrayed. The market status and SWOT analysis for different regions and countries are profiled in this report.

Global Stem Cell Antibody Market: Type Outlook:Primary Antibodies, Secondary Antibodies

Global Stem Cell Antibody Market: Application Outlook:Proteomics, DrugDevelopment, Genomics

North America (United States, Canada)Europe (Germany, France, UK, Italy, Russia, Spain)Asia Pacific (China, Japan, Korea, India, Australia, New Zealand)Middle East & Africa (Middle East, Africa)Latin America (Mexico, Brazil, C. America, Chile, Peru, Colombia)

Furthermore, the report provides the core knowledge of the market by analyzing end users consumption tendency, Stem Cell Antibody market driving factors, ever-changing market dynamics, and rising development patterns in the market.

Besides, the report focuses on the leading contenders in the Stem Cell Antibody industry and delivers an all-inclusive analysis considering their market share, production capacity, value chain analysis, size, sales and distribution network, import/export activities, cost structure, and product specification. Due to the changes in world business policies, it is recommended to be always aware of the facts and data about this market.

The study objectives of this report are:

1) To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).2) To understand the structure of the Stem Cell Antibody market by identifying its various sub-segments.3) The marketing strategies, opportunities, and Stem Cell Antibody development factors are explained.4) The competitive landscape structure, market size estimation, recent advancements in the industry are explained.5) The market dynamics, competition, and complete insights will lead to profitable business plans.6) The pricing structure covering the labor cost, raw material cost, capacity, and supply-demand statistics are presented.

The key dynamic factors that are detailed in the report:

Key Market Dynamics: The Global Stem Cell Antibody Market research report details the latest industry trends, growth patterns, and research methodologies. The factors that directly contribute to the growth of the market include the production strategies and methodologies, development platforms, and the product model itself, wherein a small change would result in further changes in the overall report. All of these factors are explained in detail in the research study.

Market Outlook: The report also sheds light on some of the major factors, including R&D, new product launches, M&A, agreements, partnerships, joint ventures, collaborations, and growth of the key industry participants, on a regional and global basis.

Major Features: The report provides a thorough analysis of some of the significant factors, which include cost, capacity, capacity utilization rate, production, revenue, production rate, consumption, import/export, supply/demand, gross, market share, CAGR, and gross margin. Besides, the report provides a comprehensive study of the key influencing factors and market inclinations, in addition to the relevant market segments and sub-segments.

Analytical Tools: The Global Stem Cell Antibody Market report consists of the precisely studied and evaluated information of the key players and their market scope using several analytical tools, including SWOT analysis, Porters five forces analysis, investment return analysis, and feasibility study. These tools have been used to efficiently study the growth of major industry participants.

Potential Customers: The report offers detailed insights to users, service providers, suppliers, manufacturers, stockholders, and individuals who are interested in evaluating and self-studying this market.

Inquiry for Buying Report: http://www.marketsnresearch.com/inquiry-for-buying.html?repid=50557

Conclusively, the report helps a reader to get an absolute understanding of the Stem Cell Antibody industry through details about the market projection, competitive scenario, industry environment, growth constraining factors, limitations, entry barriers, the provincial regulatory framework as well as upcoming market investment and opportunities, challenges and other growth-promoting factors. This report will provide you a clear view of each and every facet of the market without a need to refer to any other research report or a data source. Our report will provide you with all the facts about the past, present, and future of the concerned Market.

Sorry! The Author has not filled his profile.

Read more:
Stem Cell Antibody Market Expected to Deliver Dynamic Progression until 2028|Thermo Fisher Scientific, Inc. (US) - Industry News Info

Global CPAP Systems Market Overview:

The latest report on the global CPAP Systems market suggests a positive growth rate in the coming years. Analysts have studied the historical data and compared it with the current market scenario to determine the trajectory this market will take in the coming years. The investigative approach taken to understand the various aspects of the market is aimed at giving the readers a holistic view of the global CPAP Systems market. The research report provides an exhaustive research report that includes an executive summary, definition, and scope of the market.

Get PDF template of CPAP Systems market report@ https://www.qyresearch.com/sample-form/form/1102066/global-CPAP-Systems-market

Report in Detail

CPAP is an acronym for Continuous Positive Airway Pressure. It provides the same (continuous) level of pressure to the persons upper airway all night.The global CPAP Systems market was xx million US$ in 2018 and is expected to xx million US$ by the end of 2025, growing at a CAGR of xx% between 2019 and 2025.

This report studies the CPAP Systems market size (value and volume) by players, regions, product types and end industries, history data 2014-2018 and forecast data 2019-2025; This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porters Five Forces Analysis.

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of CPAP Systems in these regions, from 2014 to 2025, covering

North America (United States, Canada and Mexico)Europe (Germany, UK, France, Italy, Russia and Turkey etc.)Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)South America (Brazil etc.)Middle East and Africa (Egypt and GCC Countries)

The various contributors involved in the value chain of the product include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in this market include

ResMedPhilips RespironicsCompany threeDeVilbiss HealthcareApexTeijin PharmaMedtronic (Covidien)Koike MedicalFosun PharmaBMC Medical

By the product type, the market is primarily split into

Fixed Pressure CPAP DeviceAuto Adjusting CPAP Device

By the end users/application, this report covers the following segments

HospitalHome CareOthers

We can also provide the customized separate regional or country-level reports, for the following regions:

North AmericaUnited StatesCanadaMexicoAsia-PacificChinaIndiaJapanSouth KoreaAustraliaIndonesiaSingaporeMalaysiaPhilippinesThailandVietnamRest of Asia-PacificEuropeGermanyFranceUKItalySpainRussiaRest of EuropeCentral & South AmericaBrazilRest of Central & South AmericaMiddle East & AfricaGCC CountriesTurkeyEgyptSouth AfricaRest of Middle East & Africa

The study objectives of this report are:To study and analyze the global CPAP Systems market size (value & volume) by company, key regions/countries, products and application, history data from 2014 to 2018, and forecast to 2025.To understand the structure of CPAP Systems market by identifying its various subsegments.To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).Focuses on the key global CPAP Systems manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.To analyze the CPAP Systems with respect to individual growth trends, future prospects, and their contribution to the total market.To project the value and volume of CPAP Systems submarkets, with respect to key regions (along with their respective key countries).To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.To strategically profile the key players and comprehensively analyze their growth strategies.

In this study, the years considered to estimate the market size of CPAP Systems are as follows:History Year: 2014-2018Base Year: 2018Estimated Year: 2019Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million USD) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of CPAP Systems market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Key StakeholdersRaw material suppliersDistributors/traders/wholesalers/suppliersRegulatory bodies, including government agencies and NGOCommercial research & development (R&D) institutionsImporters and exportersGovernment organizations, research organizations, and consulting firmsTrade associations and industry bodiesEnd-use industries

Available CustomizationsWith the given market data, QYResearch offers customizations according to the companys specific needs. The following customization options are available for the report:Further breakdown of CPAP Systems market on basis of the key contributing countries.Detailed analysis and profiling of additional market players.

Get Customized Report in your Inbox within 24 hours@ https://www.qyresearch.com/customize-request/form/1102066/global-CPAP-Systems-market

The report is a perfect example of a detailed and meticulously prepared research study on the global CPAP Systems market. It can be customized as per the requirements of the client. It not only caters to market players but also stakeholders and key decision makers looking for extensive research and analysis on the global CPAP Systems market.

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from the huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become a brand of quality assurance in the consulting industry.

Continued here:
CPAP Systems Market Outlook, Opportunity and Demand Analysis 2019 to 2025| ResMed, Philips Respironics, Company three - Uncovering News

Many people with diabetes also experience anxiety, and they may wonder whether there is a link between the two conditions.

Diabetes and anxiety are both among the leading causes of disability in developed countries around the world.

In the United States alone, anxiety affects close to 40 million adults. Diabetes is also common, with about 30.3 million U.S. adults living with this condition.

A 2013 meta-analysis revealed that people with diabetes face a higher likelihood than the general population of experiencing anxiety.

In this article, we outline the reasons for this association. We also describe the symptoms of both diabetes and anxiety, as well as how healthcare professionals diagnose each of these conditions.

People with diabetes are responsible for managing their blood sugar levels and ensuring that these stay within a healthy range. This task can be challenging and stressful.

Doctors will ask people with diabetes to remain mindful of their blood sugar levels and to engage in routine behaviors, such as:

Planning, checking, and being prepared for a wide range of challenges are all important for effective diabetes management. However, some people may worry excessively about their blood sugar levels or how their disease may progress. These concerns may trigger episodes of anxiety.

According to the National Library of Medicine, anxiety is "excessive worry or fear at real or imagined situations."

The emotional challenges of living with diabetes can also trigger anxiety.

Researchers report that anxiety affects about 40% of people with diabetes. This prevalence is much higher than that in the general U.S. population, where the condition affects 18.1% of people.

People with diabetes are at risk of developing low blood sugar, or hypoglycemia. Some of the symptoms of hypoglycemia are identical to those of anxiety.

Additionally, the results of a 2015 animal study suggest that experiencing several episodes of hypoglycemia can increase the likelihood of anxiety. The reason for this may be that hypoglycemic episodes trigger chemical and metabolic changes that physically affect the part of the brain that plays a role in processing anxiety.

The procedures that healthcare professionals use to diagnose diabetes and anxiety are quite different.

According to the Centers for Disease Control and Prevention (CDC), doctors diagnose diabetes using one or more of the following blood tests:

A person should see their doctor if they think that they have anxiety. The doctor may ask the person to fill in a questionnaire that asks about their psychological and physical symptoms.

In some cases, a doctor may refer the person for a mental health screening with a psychiatrist or psychotherapist. These mental health professionals will be able to carry out a more detailed assessment.

People with diabetes and anxiety must learn to distinguish between rational concerns over diabetes management and irrational, anxious thinking.

The first step in this process is to work closely with healthcare professionals to develop a diabetes treatment plan. This plan should include information on the following:

For people with anxiety, many different treatment options are available. A doctor or mental health professional may recommend one or more of the following approaches:

The combination of diabetes and anxiety can create a vicious cycle of physical and emotional problems. However, people who learn to manage their anxiety may find themselves better able to manage their diabetes.

Certain lifestyle practices can be beneficial for people with diabetes, anxiety, or both. These include:

Diabetes and anxiety are two serious yet common conditions, which can share some of the same symptoms.

People with diabetes are at increased risk of developing anxiety because they may experience excessive fear and worry about the management and possible progression of diabetes. Concerns over the physical symptoms themselves can also trigger anxiety.

Anxiety can, in turn, interfere with a person's ability to manage their blood sugar levels. Due to this, a person who has diabetes should see their doctor if they begin to experience symptoms of anxiety.

Many treatment options are available to help people deal with the symptoms of diabetes and anxiety. Certain lifestyle changes may also help with the management of both conditions.

Continue reading here:
Can diabetes cause anxiety? Blood sugar and other causes - Medical News Today

LOS ANGELES Until the recentapprovalofliraglutidefor the treatment of children and adolescents with type 2 diabetes, investigators likeSonia Caprio, MD,were at their wits' end watching the beta-cell function of their patients decline on metformin treatment.

"The kids were not doing well. It was like they were being treated with water," Dr. Caprio, a pediatric endocrinologist at Yale University, New Haven, Conn., said at the annual World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease.

For example, in the NIH-fundedTODAY(Treatment Options for Type 2 Diabetes in Adolescents and Youth) study thatbegan enrollment in 2004, 699 patients aged between 10 and 17 years and with type 2 diabetes were treated with metformin (1,000 mg, twice daily) to attain a glycated hemoglobin level of less than 8% and were then randomly assigned to continued treatment withmetforminalone or to metformin combined with rosiglitazone (4 mg, twice a day) or a lifestyle-intervention program that focused on weight loss through modifying eating and activity behaviors (N Engl J Med. 2012;366:2247-56).

Over the course of 11 months, the researchers found that 46% of the children were failing treatment. "The worst arm was the metformin arm," said Dr. Caprio, who was involved with the study. "Kids were not responding to the drug at all. About 52% of children failed to do better using metformin a classic drug that we all start kids on when we diagnose them with type 2 diabetes."

Findings from a follow-up study,TODAY2, showed that these young patients were prone to serious diabetes-related events, such as heart attacks, chronic kidney disease, retinal disease, neuropathy, and complications in the offspring of pregnancies.

In addition, results from theRISE(Restoring Insulin Secretion) Pediatric Medication Study found that, in youth with impaired glucose tolerance or recently diagnosed type 2 diabetes, neither 3 months of insulin glargine followed by 9 months of metformin nor 12 months of metformin alone halted the progressive deterioration of beta-cell function (Diabetes Care. 2018;41:1717-25).

"The uniqueness ofRISEis that we employed very sophisticated techniques to measure insulin secretion and sensitivity while they were being treated with these usual drugs," said Dr. Caprio, who was one of the study investigators. "The beta cell is unresponsive to metformin and other treatments. The question is, why?"

Despite these findings, 2018 consensus guidelines from the American Diabetes Association on the evaluation and management of youth-onset diabetes (Diabetes Care. 2018;41:2648-68) call for the administration of metformin twice daily in youth with new-onset diabetes who have a hemoglobin A1c(HbA1c)level of less than 8.5%. "I argue that is not the way. We need better ways to treat [these patients] because they are moving fast to having complications," she said.

Enter theEllipse Trial, a pivotal multicenter, randomized study that evaluated the effect of the glucagonlike peptide-1 receptor agonist liraglutide in children and adolescents with type 2 diabetes (N Engl J Med. 2019;381:637-46).

Researchers, led byWilliam V. Tamborlane, MD, chief of Yale Medicine Pediatric Endocrinology, also in New Haven, randomized 135 patients to one of two arms: 66 to subcutaneous liraglutide (up to 1.8 mg/day) and 69 to placebo for a 26-week, double-blind period, followed by a 26-week open-label extension period. All patients received metformin during the trial. More than half of the study participants (62%) were female, the mean age was 15 years, 65% were white, the mean body mass index was 33.9 kg/m2, their mean fasting glucose was 8.4 mmol/L, and their mean HbA1cwas 7.8%.

At 26 weeks, the mean glycated hemoglobin level had decreased by 0.64 percentage points with liraglutide and increased by 0.42 percentage points with placebo,for an estimated treatment difference of 1.06 percentage points (Pless than .001). By 52 weeks, the difference increased to 1.30 percentage points.

"There was also a significant drop in BMIzscore in patients treated with liraglutide, which is important," Dr. Caprio said. "This medication is having an impact on weight, which is a key driver of the onset of type 2 diabetes in youth. This is a remarkable achievement because weight loss is hard to achieve in obese adolescents, as we showed in the TODAY study."

The number of adverse events reported by patients was similar in the treatment and placebo groups (85% and 81%, respectively), but the overall rates of adverse events and gastrointestinal adverse events were higher with liraglutide.

"I use liraglutide just for weight reduction because I mainly see a lot of kids with obesity. Many kids are not responding because of the GI effects of this drug. I think the weight loss could have been better had the investigators moved to a dose of 1.8 mg, which we use in adults."

A fasting plasma glucose of 6.1 mmol/L was the primary reason for participants remaining on a lower dose of liraglutide, she said. At the same time, liraglutide concentration data indicated a high rate of noncompliance, which was expected in this population. "That's a big problem we face with children," Dr. Caprio said. "Some of them are not constantly taking the medication. They skip doses a lot. But that happens with patients in this age group."

"Finally, we have something else to help children and teenagers to delay the complications we are seeing," Dr. Caprio said. "To me, I think this is a new era. I have hope. It will be interesting to see whether liraglutide and perhaps SGLT2 [sodium-glucose transporter 2] inhibitors can delay the onset of type 2 diabetes in children. In my view, we will be doing this with drugs. I don't think the weight loss [concerns are] going to go away without medication, unfortunately."

Dr. Caprio reported having no financial disclosures.

This article originally appeared on MDEdge.com.

See original here:
Could Liraglutide Stall the Onset of Type 2 Diabetes in Kids? - Medscape

Many feel like the tools available on the market werent built by people actually living with the disease, and so those with technology experience are taking matters into their own hands. In other health and technology news: virtual reality, the data Catch-22, prosthetics, cyberattacks, and Apple's push into the health industry.

The Washington Post:DIY Diabetes Tech Gains Popularity With Patients And Parents Fed Up With Clunky Mainstream Medical DevicesOne night, 18-month-old Hazel Lumpkin woke up with her diaper completely soaked with urine. Her parents, Matt and Melody Lumpkin of Pasadena, Calif., rediapered her in a larger size, hoping that would fix the issue. But Hazel continued to saturate diaper after diaper. As a childhood fan of The Baby-Sitters Club a book series featuring a young girl with Type 1 diabetes Melody recalled the connection between frequent urination and diabetes in children. (Kim, 12/14)

The Washington Post:Virtual Reality, Robots, Interactive Apps, Other New Tech Help People With Dementia And Their CaretakersDoris Moss has always loved dancing. Now in her 80s and suffering from a form of dementia, it has become more important than ever, as hearing a good beat will spur her to get up and move around. And so her daughter, Angela Pearson, who lives with her mother in Ellenwood, Ga., and is her primary caretaker, has turned to a new technology for people with Alzheimers and other forms of dementia: a touch-screen application known as SimpleC Companion, that can be set to play some of Mosss favorite music along with recorded reminders to drink water and take medication at various points of the day when Pearson is away from the house. (Kalter, 12/15)

The Washington Post:Data Catch-22: How Tech Gadgets For Exercise Sometimes Do More Harm Than GoodWhen Bri Cawsey began running in 2008, she quickly got hooked on the sport and wanted to get faster. So she did what many runners do and bought a GPS watch that would give her real-time feedback on her pace, mileage and other metrics. First, she enjoyed the data readout. Before long, she connected her watch to an app that helped her track calories, as well. Then she added a second watch, more sophisticated than the first, and began comparing the data from the two for better accuracy. By about 2012, Cawsey found she couldnt do anything without a tracking watch on her wrist. (Loudin, 12/14)

The Washington Post:New Prosthetic Can Help People Who Have Lost A Limb Feel Again, And May Reduce Phantom PainPhantom pain was all that Keven Walgamott had left of the limb he lost in an accident over a decade ago until he tried on the LUKE Arm for the first time in 2017, and told researchers that he could feel again. The arm is a motorized and sensorized prosthetic that has been in development for over 15 years by a team at the University of Utah. Researchers around the world have been developing prosthetics that closely mimic the part of the human body they would replace. (Dhar, 12/14)

The Associated Press:Large Hospital System Says It Was Hit By Ransomware AttackNew Jerseys largest hospital system said Friday that a ransomware attack last week disrupted its computer network and that it paid a ransom to stop it. Hackensack Meridian Health did not say in its statement how much it paid to regain control over its systems but said it holds insurance coverage for such emergencies. (12/13)

The Wall Street Journal:New Jersey Hospital System Hit By CyberattackAttacks on hospitals and health systems, who have been digitizing their operations and record-keeping, have proven to be hugely disruptive, in some cases leaving small physician groups unable to recover. Victims have been forced to cancel some elective procedures, shut down computer networks to prevent further spread of the virus and temporarily revert to using paper records. (Evans, 12/13)

Stat:7 Startups Acquired By Apple That Are Central To Its Health StrategyThe Apple Watch continuously monitors numerous health metrics and doubles as a virtual clinical trial site. AirPods, Apples wireless ear buds, function as basic hearing aids, and its health record app lets users pull in data from health care providers. ...Over the past decade, Apple has nabbed roughly half a dozen startups with specialties that could prove critical for health care disruption, from speech recognition and sleep tracking to health record consolidation and hospital mapping. (Brodwin, 12/16)

Follow this link:
Frustrated With Cumbersome, Clunky Diabetes Devices, Patients Are Turning To DIY Technology - Kaiser Health News

Scientists from various parts of the world involved in a $6 million dollar study have come up with an interesting revelation: Long-term remission from type 2 diabetes is possible just by losing 1 gram of fat from the pancreas. While this finding comes as a surprise to many, there are some facts about blood sugar that we are all aware of. Type 2 diabetes has a strong association with your lifestyle. What you eat determines your susceptibility to this condition and also, how well you can manage it.

Type 2diabetesaffects the bodys ability to either produce insulin or to use insulin effectively, you need treatment to keep your blood sugar levels within a normal range. Although there are numerous treatment options available to keep your blood sugar levels in control, home remedies can work wonders in achieving this task. Here are top 10 effective home remedies to maintain your blood sugar levels and lead a healthy life with diabetes.

The leaves of holy basil are packed with antioxidants and essential oils that produce eugenol, methyl eugenol and caryophyllene. Collectively these compounds help the pancreatic beta cells (cells that store and release insulin) to function properly and increase sensitivity to insulin. An added advantage is that the antioxidants present in the leaves help beat the ill effects of oxidative stress.

Tip: Consume two to three tulsi leaves whole or about one tablespoon full of its juice on an empty stomach to lower the blood sugar levels. Here are top 10 health benefits of tulsi.

Due to their high fibre content flaxseeds help digestion and aid in the proper absorption of fats and sugars. Consuming flax seed helps reduce a diabetics postprandial sugar level by almost 28 percent.

Tip: Consume one tablespoon of ground flaxseed powder every morning on an empty stomach with a glass of warm water. However, do not have more than 2 tablespoons per day, as it can be detrimental to your health. Here are 11 ways to include flaxseeds in your diet.

The leaves of bilberry have been used in Ayurveda for many centuries to control diabetes. Recently, the Journal of Nutrition stated that the leaves of the Bilberry plant contain high amounts of anthocyanidin, which enhance the action of various proteins involved in glucose transportation and fat metabolism. Due to this unique property, bilberry leaves are a great way to lower ones blood sugar levels.

Tip: Crush bilberry leaves in a mortar and pestle and consume 100 milligrams of this extract every day on an empty stomach.

Also known as dalchini, it improves insulin sensitivity and lower blood glucose levels. Having as little as teaspoon of cinnamon per day can improve ones insulin sensitivity and help controlling weight, thereby decreasing ones risk for heart disease.

Tip: Include about 1 gram of dalchini into your daily diet for about a month to help lower blood sugar levels. Read more health benefits of cinnamon.

Unlike other tea leaves, green tea is unfermented and is high in polyphenol content. Polyphenol is a strong antioxidant and hypo-glycaemic compound that helps control the release of blood sugars and helps the body use insulin better. Read more 10 types of flavoured green tea that have 20 health benefits.

Tip: Steep a bag of green tea in hot water for 2-3 minutes. Remove the bag and drink a cup of this tea in the morning or before your meals.

Also called moringa, the leaves of this plant are best known for their ability to boost ones energy. These have also been declared a superfood. In the case of diabetics, the moringa leaf increases satiety and slows the breakdown of food and lower blood pressure.

Tip: Take a few drumstick leaves, wash and crush them to extract their juice. Now take about 1/4th cup of this juice and drink it on an empty stomach, every morning to keep your sugar levels under control.

Also known as psyllium husk is often used as a laxative. When isabgol comes in contact with water, it swells to form a gel-like substance. This slows the breakdown and absorption of blood glucose. Isabgol also protects the stomach lining from ulcers and acidity.

Tip: Cosume isabgol after every meal, ideally with milk or water. Avoid having it with curd as it can lead to constipation. Read in detail about 8 health benefits of isabgol or psyllium husk you didnt know.

Bitter gourd is rich in plant insulin-polypeptide-P, a bio-chemical that mimics the insulin produced by the human pancreas and thus, reduces sugar levels in the body. It is also known to be highly beneficial for diabetics owing to thetwo very essential compounds called charatin and momordicin, which are the key compounds in lowering ones blood sugar levels.

Tip: Consume karela at least once a week either as a subzi or in a curry. If you want quick results, try having a glass of karela juice on an empty stomach once in three days. Read more about 8 healthy reasons to drink bittergourd or karela juice!

Found abundantly in India, the bitter leaf has a number of amazing medicinal properties. Neem enhances insulin receptor sensitivity, helps improve blood circulation by dilating the blood vessels, lowers blood glucose levels and reduces ones dependence on hypoglycemic drugs. Here are more health benefits of neem.

Tip: Drink the juice of the tender shoot of neem leaves on an empty stomach for best results.

A glycoside present in the seeds of Indian blackberry prevents the conversion of starch to sugar. It lowers blood sugar and helps prevent insulin spikes. Jambul also has properties that can protect you from heart diseases and other vascular disorders.

Tip: Eat around 5 6 jamuns in the morning to control your blood sugar levels. Alternatively, you can also add a spoonful of jamun seeds powder to a glass of warm water or milk and drink this daily for better control of diabetes.

Published : December 16, 2019 4:10 pm | Updated:December 17, 2019 11:06 am

Read the original post:
Top 10 diabetes home remedies that tame your blood sugar levels - TheHealthSite

People with diabetes are at increased risk ofdevelopingseriouseye diseases, yet most do not have sight-saving annual eyeexams,accordingtoalargestudy.

TheKentucky Academy of Eye Physicians and Surgeonsjoins theAmerican Academy of Ophthalmologyin reiterating the importance of eye exams.

Researchers at Wills Eye Hospital in Philadelphia have found that more than half of patientswith the disease skip these exams. They also discovered that patients who smoke and those with less severe diabetes and no eye problems were mostlikely to neglect having these checks.

The researcherscollaborated with the Centers for DiseaseControl and Prevention toreviewthe charts of close to 2,000 patientsage 40 or older with type 1and type 2 diabetes to see how many had regular eye exams.Their findings over a four-year period revealed that:

Fifty-eight percent of patients did not have regularfollow-upeye exams. Smokers were20 percent less likelyto have exams. Thosewith less-severe disease and no eye problems were least likely tofollow recommendations. Those who had diabetic retinopathy were 30 percent more likely to have follow-up exams.

One in 10 Americans have diabetes, putting them at heightened risk for visual impairment due to the eye diseasediabetic retinopathy.The diseasealso can lead to other blinding ocular complications if not treated in time.Fortunately, having adilated eye exam yearly or more often can prevent 95 percent of diabetes-related visionloss.

Eye exams are critical as they can reveal hidden signs of disease, enabling timely treatment.This is why the Academy recommends people with diabetes have them annually or more often as recommended by their ophthalmologist, a physician who specializes in medical and surgical eye care.

Vision loss is tragic, especially when it is preventable, said Ann P. Murchison, M.D., M.P.H., lead author of the study and director of the eye emergency department at Wills Eye Hospital. Thats whywe want to raise awareness and ensure people with diabetes understand the importance ofregular eye exams.

The Academy offers thisanimated public service announcementto help educate people about the importance of regular exams and common eye diseases including diabetic retinopathy. It encourages the public to watch and share it with their friends and family.

People with diabetes need to know that they shouldnt wait until they experience problems to get these exams, Rahul N. Khurana, M.D, clinical spokesperson for the Academy. Getting your eyes checked by an ophthalmologist can reveal the signs of disease that patients arent aware of.Diabetic retinopathy, much like glaucoma, can be insidious in its ability to cause vision loss, said Thomas Harper, M.D., an ophthalmologist in Louisville.

It is common to have diabetic retinopathy without having any symptoms.Once symptoms manifest, retinopathy can be quite advanced.Even though it is a bit of an oversimplification, there are two types of people who go blind from diabetes: those who dont control his or her diabetes, and those who dont go to the eye doctor. Schedule your retina exam today.

Kentucky Academy of Eye Physicians and Surgeons

See the rest here:
People with diabetes should get annual eye exams it's very possible that vision loss can be preventable - User-generated content